Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
Single-dose intranasal mebufotenin reduced depressive symptoms through day 57 compared with a low-dose comparator in adults with treatment-resistant depression. The phase 2b trial also assessed adverse events and postdose discharge readiness.
Psychiatric Pharmacy (BCPP) November 20th 2026
News Medical
In mice, psilocybin accelerated dendritic spine formation and maturation, with different remodeling patterns in stressed and healthy brains. Genetic experiments separated these structural effects from head-twitch behavior, a proxy rather than a direct measure of hallucinations.
Clinical Pharmacology November 10th 2026
Medical Professionals Reference (MPR)
The FDA has approved once-monthly subcutaneous olanzapine for adults with schizophrenia, supported by placebo-controlled trial data showing symptom improvement and sustained efficacy through 48 weeks, while eliminating several logistical requirements associated with treatment initiation.
Behavioral Health October 20th 2026
Psychiatrist.com
A single-day inhaled mebufotenin regimen produced rapid, sustained symptom reductions through day 8 in 10 patients with postpartum depression, but the uncontrolled trial provides an early clinical signal rather than comparative efficacy evidence.
Clinical Pharmacology October 9th 2026
A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.
Behavioral Health September 25th 2026
Physical symptoms following antidepressant cessation are generally transient and consistent with established discontinuation phenomena, while persistent or delayed symptoms remain difficult to explain pharmacodynamically and may involve psychiatric, psychological, or somatic contributors.
Behavioral Health September 4th 2026